Managing Adjuvant Treatment in Colorectal Cancer, Part II
Panelists: Johanna Bendell, MD, Sarah Cannon; Axel Grothey, MD, Mayo Clinic; Claus-Henning Köhne, MD, PhD, Klinikum Oldenburg; John L. Marshall, MD, Georgetown-Lombardi; Heinz-Josef Lenz, MD, USC Norris
Published Online: Friday, April 5, 2013
For High-Definition, Click
Researchers continue to explore the optimal duration of adjuvant chemotherapy for patients with colorectal cancer (CRC). As more data become available the standard duration has slowly declined from 18 months to the current standard of 12 cycles over the course of 6 months and a 3-month course is currently being examined.
Claus-Henning Kohne, MD, PhD, believes the most exciting research currently in stage III CRC is the examination of ever-shorter durations of treatment. Moreover, Kohne notes, it remains unclear whether FOLFOX is the optimal treatment in this space.
Axel Grothey, MD, states that approximately two-thirds of adjuvant FOLFOX efficacy is derived from fluoropyrimidine and one-third from oxaliplatin. As side effects occur, it may become necessarily to omit oxaliplatin from the regimen. In general, Grothey finds, it is a rare event for patients to complete 12 full cycles of adjuvant FOLFOX and as a result it may be best to back off treatment.
In stage II disease, Kohne and other members of the panel are reluctant to offer oxaliplatin. In general, many of the benefits of FOLFOX are derived by fluoropyrimidine alone. Omitting oxaliplatin remains especially beneficial for elderly patients, Kohne notes. However, some patients with high risk factors may still be candidates for this treatment, causing even further uncertainty. In general, the dilemma of determining which patients benefit the most from adjuvant therapy calls for effective predictive markers.
Johanna Bendell, MD, notes that studies are currently looking at high microsatellite instability (MSI) or DNA Mismatch Repair (MMR) deficiency as an indicator of resistance to fluorouracil therapy, which denotes less benefit from adjuvant therapy. Additionally, she adds, patients with Lynch Syndrome should also receive genetic testing.
In terms of gene profiling, the panel does not feel confident in the predictive accuracy of commercially available tests. In general, they feel these test are not adequately explaining recurrence and need to be further refined. The effectiveness of these tests is further confounded by non-concordant results between tests.
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.